FDA un­veils 5 guid­ances on broad­en­ing can­cer clin­i­cal tri­al el­i­gi­bil­i­ty

As part of a push to trans­form clin­i­cal tri­al el­i­gi­bil­i­ty cri­te­ria that have been ac­cept­ed over time with­out a clear sci­en­tif­ic or clin­i­cal ra­tio­nale, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER